吡柔比星为主联合化疗方案治疗老年非霍奇金淋巴瘤临床研究.docVIP

吡柔比星为主联合化疗方案治疗老年非霍奇金淋巴瘤临床研究 　　[摘要] 目的:观察吡柔比星为主的联合化疗方案(CTOP方案)治疗老年非霍奇金淋巴瘤(NHL)的临床疗效。方法:将我院2008年2月～2009年4月收治的61例老年NHL患者随机分为观察组(31例)和对照组(30例),分别采用CTOP方案和CHOP方案治疗。结果:观察组的完全缓解率高于对照组,两组差异有统计学意义(P0.05);观察组的不良反应发生率低于对照组,两组差异有统计学意义(P0.05)。结论:CTOP方案治疗老年NHL疗效满意,且不良反应少,是目前治疗老年NHL的理想方法之一。 　　[关键词] 非霍奇金淋巴瘤;老年;吡柔比星;阿霉素;化疗 　　[中图分类号] R551.2[文献标识码]A [文章编号]1673-7210(2010)02(a)-009-02 　　 　　Clinical study of CTOP regimen in the treatment of aged patients with NHL 　　ZHANG Yusheng 　　(The First Peoples Hospital of Shangqiu City, Henan Province, Shangqiu 476000, China) 　　[Abstract] Objective: To investigate the therapeutic effects of CTOP regimen in the treatment of aged patients with NHL. Methods: 61 aged patients with NHL from February 2008 to April 2009 in our hospital were randomly divided into observation group (n=31) and control group (n=30), and they were treated with CTOP regimen and CHOP regimen respectively. Results: The complete remission rate of the observation group was higher than that of control group, and they showed a significant difference (P0.05); the incidence of adverse reactions of the observation group was lower than that of control group, and they showed a significant difference (P0.05). Conclusion: CTOP regimen in the treatment of aged patients with NHL has satisfactory effect and few adverse reactions, it is one of the ideal methods for the treatment of aged patients with NHL. 　　[Key words] Non-Hodgkins lymphoma; Aged; THP; ADM; Chemotherapy 　　 　　非霍奇金淋巴瘤(non-Hodgkins lymphoma,NHL)较霍奇金病常见,各年龄组均可发生,发病率随年龄增长而升高[1]。其治疗与霍奇金病相似,主要方法是放疗、化疗和其他辅助治疗或三者合用。本研究旨在观察吡柔比星(THP)为主的联合化疗方案(CTOP方案)治疗老年NHL的临床疗效,以期为临床提供参考。 　　1 资料与方法 　　1.1一般资料 　　我院2008年2月～2009年4月收治61例老年NHL患者,所有患者均经病理组织学证实,治疗前无心脏疾病,肝、肾功能正常。其中,男性40例,女性21例;年龄65～79岁,平均(68.2±0.7)岁;初治患者44例,复治患者17例;临床分期:Ⅰ期10例,Ⅱ期25例,Ⅲ期19例,Ⅳ期7例。将所有患者随机分为观察组(31例)和对照组(30例),两组患者一般资料比较,差异无统计学意义(P0.05),具有可比性。 　　1.2治疗方法 　　对照组采用CHOP方案治疗:CTX 750 mg/m2,静脉推注,第1天;阿霉素(ADM)50 mg/m2,静脉推注,第1天;长春新碱(VCR)1.4 mg/m2,静脉推注,第1天:泼尼松(PDN)50 mg,每天2次,口服,第1～5